Research programme: LIM kinase inhibitor - Aegera Therapeutics
Latest Information Update: 05 Mar 2007
At a glance
- Originator Aegera Therapeutics
- Class Small molecules
- Mechanism of Action LIM kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Mar 2007 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 01 Sep 2005 Preclinical trials in Cancer in Canada (unspecified route)